Merck topped Wall Street's fourth-quarter expectations Tuesday, but Merck stock could take a hit on lighter-than-expected 2025 sales guidance.

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, although the drug company’s outlook for 2025 ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% ...

Below are the earnings highlights for Merck & Co Inc. (MRK): Earnings: $3.743 billion in Q4 vs. -$1.226 billion in the same period ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...